Phosplatin Therapeutics

2:15 PM - 2:30 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
The Company is engaged in the clinical development of its novel small molecule, PT-112, a first-in-class pyrophosphate conjugate with a pleiotropic mechanism of action (MOA) that promotes immunogenic cell death (ICD) without evidence of DNA damage.
The Company is currently engaged in three Phase Ib/IIa clinical trials crossing solid tumors and hematological malignancies, having completed its requisite EOP1 meeting with the FDA. In addition, the Company is engaged in a Clinical Trial Collaboration with Pfizer and Merck KGaA (EMD Serono) investigating the combination of PT-112 with avelumab, a PD-L1 checkpoint inhibitor.
The Company was awarded best poster amongst 50+ candidates in the Developmental Therapeutics category at ESMO 2018. In addition, PT-112's potent induction of immunogenic cell death was the subject of a poster presentation at the 4th Quad International Immunotherapy Conference 2018. PT-112 was also featured in posters presented at ASCO and ASH in 2017.
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
Lead Product in Development:
PT-112
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
N/A
Speaker
photo
President & CEO
Phosplatin Therapeutics